Filing summary
Entity and period: The supplied filing is OvaScience, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015—not a Tempest Therapeutics filing. The company described itself as a fertility-treatment developer and early-stage commercial business.
Financial results and liquidity
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $30,000 | $45,000 | None reported |
| Cost of revenue | $116,000 | $151,000 | None reported |
| Research and development | $4.0 million | $9.8 million | $4.5 million and $9.2 million |
| Selling, general and administrative | $13.1 million | $24.1 million | $5.1 million and $8.1 million |
| Net loss | $17.5 million | $34.7 million | $9.9 million and $17.7 million |
| Net loss per share | $0.64 | $1.29 | $0.42 and $0.83 |
| Operating cash used | — | $26.4 million | $11.5 million |
Revenue remained minimal, and cost of revenue exceeded revenue in the reported periods. No positive gross margin was reported. SG&A growth, primarily related to hiring and international commercialization, drove much of the higher operating loss. Stock-based compensation was $10.7 million for the first half, versus $3.1 million a year earlier.
At June 30, cash and cash equivalents were $70.2 million and short-term investments were $85.4 million, totaling $155.6 million; working capital was $151.6 million. Total liabilities were $7.7 million, with no debt balance identified in the supplied filing text. The company reported a $129.4 million accumulated deficit. First-half financing provided $125.4 million, principally from a January public offering that generated $124.1 million net. Management estimated existing cash and investments would fund its current operating plan at least into 2017, while cautioning that assumptions could prove wrong.
Changes and business developments
- First-half net loss increased 96% year over year; SG&A increased 199%, while R&D increased 6%.
- Cash and short-term investments rose from $60.2 million at December 31, 2014, mainly following the $124.1 million equity offering. Common shares issued increased during the period.
- AUGMENT, the company’s first treatment, was being offered in select international IVF clinics; it was not available in the United States. The company reported $45,000 of first-half treatment revenue and said payments may precede treatment delivery, with revenue recognition typically 30–120 days later and potentially longer in some programs.
- OvaPrime and OvaTure remained in development. The company planned to introduce OvaPrime in at least one international region by year-end 2015 and to optimize OvaTure and define its development pathway during 2015.
- In May 2015, the company signed a Waltham office and laboratory lease through November 2020. Stated minimum annual payments range from approximately $0.1 million for the remainder of 2015 to $1.0 million in 2018 and 2019. A $0.4 million cash-collateralized letter of credit was recorded as restricted cash; the landlord offered up to $1.2 million in tenant improvements.
Outlook, risks and contingencies
- Management continued to target 1,000 AUGMENT cycles in 2015 and expected a significant treatment increase in the second half, with most of that increase expected to be recognized as revenue or deferred revenue in the fourth quarter. Achievement depended on uptake at existing and new clinics and reimbursement initiatives.
- The filing reports that, in August 2015, a UAE national healthcare provider determined to reimburse eligible patients for AUGMENT. This is a post-quarter development described in the filing; actual uptake and resulting revenue were uncertain.
- The company expected continued operating losses and significant expenses for at least several years. It had no committed external funding source and warned that it might need additional capital; equity financing could dilute shareholders, while other financing or partnership arrangements could impose restrictions or require granting rights.
- Commercialization, treatment adoption, regulatory or institutional review, clinical and development outcomes, competition, intellectual-property protection, and the ability to obtain funding were material risks. Management said development costs and timing could not be reliably estimated.
- A shareholder class action alleging securities-law misrepresentations about AUGMENT’s regulatory status was pending; the company’s motion to dismiss had not been ruled on. The company said it believed the action lacked merit, but could not assess its likely outcome or materiality.
- A hypothetical 100-basis-point interest-rate increase was estimated to reduce investment fair value by approximately $0.7 million. Management said it could hold fixed-income investments to maturity and did not expect a significant operating or cash-flow effect.
Key facts for investors to verify
- Confirm the issuer identity: the supplied document is OvaScience, Inc.’s 2015 Q2 10-Q, despite the request metadata naming Tempest Therapeutics.
- Check subsequent filings for actual AUGMENT treatment volumes, recognized and deferred revenue, reimbursement coverage and commercial uptake against the 1,000-cycle target.
- Assess cash burn and runway against management’s “at least into 2017” estimate, including commercialization spending and lease obligations.
- Review the scientific, clinical and regulatory evidence supporting AUGMENT and the development progress of OvaPrime and OvaTure; reported clinic experience and births in this filing are company commentary, not financial performance measures.
- Track the class action, potential future financing and dilution, and the accounting and economic effects of stock-based compensation.